Table Of Contents
REPORT PROLOGUE
MARKET INTRODUCTION
2.1. Definition
2.2. Scope Of The Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
MARKET FACTOR ANALYSIS
5.1. Porterโs Five Forces Analysis
5.1.1. Bargaining Power Of Suppliers
5.1.2. Bargaining Power Of Buyers
5.1.3. Threat Of New Entrants
5.1.4. Threat Of Substitutes
5.1.5. Intensity Of Rivalry
5.2. Value Chain Analysis
GLOBAL DIABETIC RETINOPATHY MARKET, BY TYPE
6.1. Overview
6.2. Non-Proliferative
Market Estimates & Forecast, By Region, 2020โ2027
Market Estimates & Forecast, By Country, 2020โ2027
6.3. Proliferative
Market Estimates & Forecast, By Region, 2020โ2027
Market Estimates & Forecast, By Country, 2020โ2027
GLOBAL DIABETIC RETINOPATHY MARKET, BY TREATMENT
7.1. Overview
7.2. Anti-VEGF Drugs
Market Estimates & Forecast, By Region, 2020โ2027
Market Estimates & Forecast, By Country, 2020โ2027
7.3. Laser Photocoagulation
Market Estimates & Forecast, By Region, 2020โ2027
Market Estimates & Forecast, By Country, 2020โ2027
7.4. Vitreoretinal Surgery
Market Estimates & Forecast, By Region, 2020โ2027
Market Estimates & Forecast, By Country, 2020โ2027
7.5. Steroid Injection
Market Estimates & Forecast, By Region, 2020โ2027
Market Estimates & Forecast, By Country, 2020โ2027
GLOBAL DIABETIC RETINOPATHY MARKET, BY END USER
8.1. Overview
8.2. Hospitals
Market Estimates & Forecast, By Region, 2020โ2027
Market Estimates & Forecast, By Country, 2020โ2027
8.3. Ambulatory Surgical Centers
Market Estimates & Forecast, By Region, 2020โ2027
Market Estimates & Forecast, By Country, 2020โ2027
8.4. Others
Market Estimates & Forecast, By Region, 2020โ2027
Market Estimates & Forecast, By Country, 2020โ2027 9. GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest Of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest Of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
COMPANY LANDSCAPE
10.1.1. Overview
10.1.2. Competitive Analysis
COMPANY PROFILES
11.1. F. Hoffmann-La Roche AG
11.1.1. Overview
11.1.2. Product Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Regeneron Pharmaceuticals, Inc.
11.2.1. Overview
11.2.2. Product Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Alimera Sciences
11.3.1. Overview
11.3.2. Product Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Ampio Pharmaceuticals Inc.
11.4.1. Overview
11.4.2. Product Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Aurolab
11.5.1. Overview
11.5.2. Product Overview
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Allergan PLC
11.6.1. Overview
11.6.2. Product Overview
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Abbott Laboratories
11.7.1. Overview
11.7.2. Product Overview
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Others
APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL DIABETIC RETINOPATHY MARKET SYNOPSIS, 2020โ2027
TABLE 2 GLOBAL DIABETIC RETINOPATHY MARKET ESTIMATES AND FORECAST, 2020โ2027 (USD MILLION)
TABLE 3 GLOBAL DIABETIC RETINOPATHY MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 4 GLOBAL DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020โ2027 (USD MILLION)
TABLE 5 GLOBAL DIABETIC RETINOPATHY MARKET, BY END USER, 2020โ2027 (USD MILLION)
TABLE 6 GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION, 2020โ2027 (USD MILLION)
TABLE 7 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 8 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020โ2027 (USD MILLION)
TABLE 9 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, BY END USER, 2020โ2027 (USD MILLION)
TABLE 10 US: DIABETIC RETINOPATHY MARKET, BY DRUG CLASS, 2020โ2027 (USD MILLION)
TABLE 11 US: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020โ2027 (USD MILLION)
TABLE 12 US: DIABETIC RETINOPATHY MARKET, BY END USER, 2020โ2027 (USD MILLION)
TABLE 13 CANADA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 14 CANADA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020โ2027 (USD MILLION)
TABLE 15 CANADA: DIABETIC RETINOPATHY MARKET, BY END USER, 2020โ2027 (USD MILLION)
TABLE 16 LATIN AMERICA: DIABETIC RETINOPATHY MARKET, BY DRUG CLASS, 2020โ2027 (USD MILLION)
TABLE 17 LATIN AMERICA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020โ2027 (USD MILLION)
TABLE 18 LATIN AMERICA: DIABETIC RETINOPATHY MARKET, BY END USER, 2020โ2027 (USD MILLION)
TABLE 19 EUROPE: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 20 EUROPE: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020โ2027 (USD MILLION)
TABLE 21 EUROPE: DIABETIC RETINOPATHY MARKET, BY END USER, 2020โ2027 (USD MILLION)
TABLE 22 WESTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 23 WESTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020โ2027 (USD MILLION)
TABLE 24 WESTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY END USER, 2020โ2027 (USD MILLION)
TABLE 25 EASTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 26 EASTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020โ2027 (USD MILLION)
TABLE 27 EASTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY END USER, 2020โ2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020โ2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY END USER, 2020โ2027 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020โ2027 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: DIABETIC RETINOPATHY MARKET, BY END USER, 2020โ2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR GLOBAL DIABETIC RETINOPATHY MARKET
FIGURE 3 MARKET DYNAMICS FOR GLOBAL DIABETIC RETINOPATHY MARKET
FIGURE 4 GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY TYPE, 2020 (%)
FIGURE 5 GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY TREATMENT, 2020 (%)
FIGURE 6 GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY END USER, 2020 (%)
FIGURE 7 GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY REGION, 2020 (%)
FIGURE 8 NORTH AMERICA: DIABETIC RETINOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 9 EUROPE: DIABETIC RETINOPATHY MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 WESTERN EUROPE: DIABETIC RETINOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 MIDDLE EAST & AFRICA: DIABETIC RETINOPATHY MARKET SHARE, BY REGION, 2020 (%)
FIGURE 13 GLOBAL DIABETIC RETINOPATHY MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 14 F. HOFFMANN-LA ROCHE AG: KEY FINANCIALS
FIGURE 15 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE
FIGURE 16 F. HOFFMANN-LA ROCHE AG: GEOGRAPHICAL REVENUE
FIGURE 17 REGENERON PHARMACEUTICALS, INC.: KEY FINANCIALS
FIGURE 18 REGENERON PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
FIGURE 19 REGENERON PHARMACEUTICALS, INC.: GEOGRAPHICAL REVENUE
FIGURE 20 ALIMERA SCIENCES: KEY FINANCIALS
FIGURE 21 ALIMERA SCIENCES: SEGMENTAL REVENUE
FIGURE 22 ALIMERA SCIENCES: GEOGRAPHICAL REVENUE
FIGURE 23 AMPIO PHARMACEUTICALS INC.: KEY FINANCIALS
FIGURE 24 AMPIO PHARMACEUTICALS INC.: SEGMENTAL REVENUE
FIGURE 25 AMPIO PHARMACEUTICALS INC.: GEOGRAPHICAL REVENUE
FIGURE 26 AUROLAB: KEY FINANCIALS
FIGURE 27 AUROLAB: SEGMENTAL REVENUE
FIGURE 28 AUROLAB: GEOGRAPHICAL REVENUE
FIGURE 29 ALLERGAN PLC: KEY FINANCIALS
FIGURE 30 ALLERGAN PLC: SEGMENTAL REVENUE
FIGURE 31 ALLERGAN PLC: GEOGRAPHICAL REVENUE
FIGURE 32 ABBOTT LABORATORIES: KEY FINANCIALS
FIGURE 33 ABBOTT LABORATORIES: SEGMENTAL REVENUE
FIGURE 34 ABBOTT LABORATORIES: GEOGRAPHICAL REVENUE